Evidence map›Paper›PMID 28193626›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017

Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.

Orin Bloch, Michael Lim, Michael E Sughrue, Ricardo J Komotar, John M Abrahams, Donald M O'Rourke, Anthony D'Ambrosio, Jeffrey N Bruce, Andrew T Parsa

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00905060 (PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme), which is not on this map. Cited by 76 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 4 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00905060 phase2completednot on this map

PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

TypeinterventionalSponsorUniversity of California, San FranciscoRan2009 to 2014Enrolled70ConditionsBrain and Central Nervous System TumorsArmsHSPPC-96, Temozolomide, Standard Surgical Resection
3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 4 syntheses or guidelines pooled it, 115 citations in OpenAlex.

  1. A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Pooled it
  2. Pooled it
  3. Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2022
    Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Orin BlochDepartment of Neurological Surgery, Northwestern University, Chicago, Illinois. orin.bloch@northwestern.edu.
Michael LimDepartment of Neurosurgery, Johns Hopkins University, Baltimore, Maryland.
Michael E SughrueDepartment of Neurosurgery, University of Oklahoma, Oklahoma City, Oklahoma.
Ricardo J KomotarDepartment of Neurosurgery, University of Miami, Miami, Florida.
John M AbrahamsNorthern Westchester Hospital, Mount Kisco, New York.
Donald M O'RourkeDepartment of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania.
Anthony D'AmbrosioThe Valley Hospital, Paramus, New Jersey.
Jeffrey N BruceDepartment of Neurological Surgery, Columbia University, New York, New York.
Andrew T ParsaDepartment of Neurological Surgery, Northwestern University, Chicago, Illinois.
Johns Hopkins University · USUniversity of Oklahoma · US

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
B7H1 Mediated Immunosuppression in GliomaR01CA164714 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BLOCH, ORIN · 2013 to 2018
$1.6M
B7-H1 Expressing Macrophages Mediate Immunosupression in GliomaR00NS078055 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BLOCH, ORIN · 2014 to 2016
$747k
NCI NIH HHS P50 CA097257NCI NIH HHS R01 CA164714NINDS NIH HHS R00 NS078055
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedB7-H1 AntigenDisease-Free SurvivalDNA MethylationFemaleGene Expression Regulation, NeoplasticGlioblastomaHeat-Shock ProteinsHumansKaplan-Meier EstimateMaleMiddle AgedPeptidesPrognosisProgrammed Cell Death 1 ReceptorB7-H1 AntigenCD274 protein, humanHeat-Shock ProteinsPDCD1 protein, humanPeptidesProgrammed Cell Death 1 ReceptorVaccines, Subunit

Identifiers

PMID28193626
PMCPMC5511566
OpenAlexW2588896788

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.